Patents Assigned to Biogen Idec
  • Utilization of dialkylfumarates
    Patent number: 7915310
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: March 29, 2011
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Antibodies to VLA-1
    Patent number: 7910099
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: March 22, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Carbocyclic and oxacarbocyclic fumaric acid oligomers
    Patent number: 7906659
    Abstract: The present invention relates to certain carbocyclic and oxacarbocyclic fumaric acid oligomers and the use thereof for preparing a pharmaceutical preparation as well of pharmaceutical preparations containing these compounds.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: March 15, 2011
    Assignee: Biogen IDEC International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • TAJ in Neuronal Function
    Publication number: 20110052500
    Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
    Type: Application
    Filed: August 17, 2010
    Publication date: March 3, 2011
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha Mi, Jeffrey L. Browning
  • SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING
    Publication number: 20110046073
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-?.receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-?.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 24, 2011
    Applicant: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Cripto blocking antibodies and uses thereof
    Patent number: 7888052
    Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: February 15, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
  • Humanized antibodies against monocyte chemotactric proteins
    Patent number: 7888479
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: February 15, 2011
    Assignee: Biogen Idec Ma Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
  • MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
    Publication number: 20110021513
    Abstract: The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.
    Type: Application
    Filed: September 7, 2007
    Publication date: January 27, 2011
    Applicant: Biogen Idec Ma Inc.
    Inventors: Thomas Durand-Reville, Charles Jewell, Charles Hammond, Donovan Chin
  • MODIFIED ANTIBODIES AND METHODS OF USE
    Publication number: 20110020222
    Abstract: Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.
    Type: Application
    Filed: May 28, 2010
    Publication date: January 27, 2011
    Applicant: BIOGEN IDEC MA Inc.
    Inventors: Gary R. Braslawsky, Nabil Hanna, Paul Chinn
  • TWEAK RECEPTOR AGONISTS AS ANTI-ANGIOGENIC AGENTS
    Publication number: 20110002924
    Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
    Type: Application
    Filed: April 7, 2010
    Publication date: January 6, 2011
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
  • Antibodies having altered effector function and methods for making the same
    Patent number: 7863419
    Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: January 4, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Frederick R. Taylor, Ellen Garber
  • CRIPTO BINDING MOLECULES
    Publication number: 20100330081
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof and their use in treating disorders, such as cancer either alone or in combination with other agents.
    Type: Application
    Filed: June 2, 2008
    Publication date: December 30, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Michele Sanicola-Nadel
  • Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BAFFR
    Patent number: 7850967
    Abstract: Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administration.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: December 14, 2010
    Assignee: Biogen IDEC MA Inc.
    Inventors: Susan Kalled, Sambasiva Rao
  • Methods of Manufacturing a Biologic Using a Stable Storage Intermediate
    Publication number: 20100310548
    Abstract: The present invention is directed to methods of isolating and purifying protein from a bioreactor process. The invention relates to employing a protein phase separation methodology to isolate or purify protein product in the forms of solid, semi-solid, or suspension during a protein manufacturing purification process as a stable storage intermediate. This approach is designed to allow the isolated protein product (purified or partially purified) to be stored over an extended period of time prior to further protein purification steps.
    Type: Application
    Filed: October 15, 2008
    Publication date: December 9, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Ping Yeh, Jorg Thommes, Jorg Thommes, Wolfgang Noe, Wolfgang Berthold
  • Methods of promoting neurite outgrowth with soluble TAJ polypeptides
    Patent number: 7846438
    Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: December 7, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, Jeffrey L. Browning
  • BIOMARKERS FOR PREDICTING ANTI-TNF RESPONSIVENESS OR NON-RESPONSIVENESS
    Publication number: 20100303813
    Abstract: The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 2, 2010
    Applicants: Biogen Idec MA Inc., The Feinstein Institute for Medical Research
    Inventors: John P. Carulli, Peter K. Gregersen, Franak Batliwalla, Jadwiga Bienkowska, Chunyu Liu
  • Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
    Publication number: 20100297121
    Abstract: This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 25, 2010
    Applicant: Biogen Idec MA Inc.
    Inventor: Sha Mi
  • Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
    Patent number: 7838639
    Abstract: Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bind to TRAIN are useful in regulating cell differentiation, death, and survival. Other embodiments of the invention encompass pharmaceutical compositions comprising antibodies that bind to human TRAIN.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 23, 2010
    Assignees: Biogen Idec MA Inc., Apoxis S.A.
    Inventors: Jurg Tschopp, Catherine Hession
  • NOVEL NEUROTROPHIC FACTORS
    Publication number: 20100292142
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: December 7, 2009
    Publication date: November 18, 2010
    Applicants: BIOGEN IDEC MA INC., NSGENE A/S
    Inventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Aadenosine receptor antagonists
    Patent number: 7834014
    Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: November 16, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Hairuo Peng, Gang Yao, Russell C. Petter, Gnanasambandam Kumaravel